| Lexi Jeanne Kahn, OTR | |
|
1204 Quari St, Aurora, CO 80011-6225 | |
| (847) 962-9380 | |
| Not Available |
| Full Name | Lexi Jeanne Kahn |
|---|---|
| Gender | Female |
| Speciality | Occupational Therapist |
| Location | 1204 Quari St, Aurora, Colorado |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1144940958 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225X00000X | Occupational Therapist | OT.0007575 (Colorado) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Lexi Jeanne Kahn, OTR 1204 Quari St, Aurora, CO 80011-6225 Ph: () - | Lexi Jeanne Kahn, OTR 1204 Quari St, Aurora, CO 80011-6225 Ph: (847) 962-9380 |
News Archive
Recently, researchers from the UK and Sweden used highly sensitive multiplexed immunohistochemistry to study the brain tissue of COVID-19 patients and controls to analyze ACE2 expression in brain pericytes of patients with neurological symptoms. They also used spatial immunophenotyping to assess inflammation in brain tissue of COVID-19 patients.
Research on children orphaned by HIV/AIDS in South Africa may provide insight on how to identify and help children with emotional behavior issues in other areas of the world, which may have limited access to healthcare and further research that could lead to successful interventions.
A targeted therapy drug used for breast and kidney cancers may also extend progression-free survival for patients with advanced head and neck cancer who are at high risk for recurrence after standard treatment.
Ligand Pharmaceuticals Incorporated announced today that its research collaboration with Pfizer for JAK3 has been extended by one year. The Research and License Agreement entered into in December 2006 with Wyeth provided for an initial three year research term. Under this extension, Ligand will receive $3.1 million in research payments to continue conducting drug discovery and lead candidate optimization.
Vertex Pharmaceuticals Incorporated announced today that the European Commission has approved KALYDECOTM (ivacaftor) for people with cystic fibrosis (CF) ages 6 and older who have at least one copy of the G551D mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
› Verified 8 days ago
Ms. Carol Yvonne Wall, O.T.R., C.E.A.S Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 3451 S Chambers Rd, Aurora, CO 80014 Phone: 303-680-6121 Fax: 303-680-8627 | |
Hatti Owens, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 15751 E 1st Ave, Aurora, CO 80011 Phone: 303-340-0510 | |
Mrs. Sanja June Batz, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 13123 E 16th Ave, Aurora, CO 80045 Phone: 720-777-7447 | |
Lilly O'toole, OTD Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 7795 S Blackstone Pkwy, Aurora, CO 80016 Phone: 720-886-1400 | |
Susanna Muth, OTR Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 24300 E Progress Dr, Aurora, CO 80016 Phone: 720-886-4000 | |
Alexis Reinert, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 5954 S Quatar Ct, Aurora, CO 80015 Phone: 303-250-4291 Fax: 720-306-2352 | |
Alyssa Fasoli, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 15701 E 1st Ave Ste 109, Aurora, CO 80011 Phone: 303-367-3060 |